検索ワード: plasma exchange (英語 - マルタ語)

plasmapheresis or plasma exchange
plażmaferesi jew skambju ta’ plażma

plasma
limfa

infusion plasma
ta ’ plasma

plasma concentrations.
konċentrazzjonijiet ta’ antiarritmiċi fil

plasma hiv-rna
plażma hiv-rna

300 mg per each plasmapheresis or plasma exchange session
300 mg għal kull plażmaferesi jew sessjoni ta’ skambju ta’ plażma

argon plasma arc
ark tal-plażma bl-argon

plasma zn2+ concentration
konċentrazzjoni zn2+ fil-plażma

bedaquiline plasma exposures
delamanid:

human plasma protein...................................................................................................................
proteina tal-plażma umana ............................................................................................................

discontinued; therefore plasma
għalhekk għandu jiġi mmonitorjat

plasma caffeine concentrations have been shown to decrease after exchange transfusion.
il-konċentrazzjonijiet ta’ caffeine fil-plażma intwerew li jonqsu wara trasfużjoni ta’ tibdil.

neither dialysis nor plasma exchange results in removal of fingolimod from the body.
la l-bdil tal-likwidu tad-dijaliżi u lanqas il-bdil tal-plażma ma jwasslu għat-tneħħija ta’ fingolimod mill-ġisem.

the clearance and half-life of eculizumab were also evaluated during plasma exchange interventions.
it-tneħħija u l-half-life ta’ eculizumab ġew evalwati wkoll waqt interventi ta’ skambju ta’ plażma.

the second study involved 20 patients with ahus who were already receiving plasma exchange or infusion.
fit-tieni studju ħadu sehem 20 pazjent bl-ahus li diġà kienu qed isirilhom skambju plażmiku jew infużjoni.

the effect of plasma exchange on natalizumab clearance and pharmacodynamics was evaluated in a study of 12 ms patients.
l-effett ta’ tibdil fil-plażma fuq it-tneħħija u l-farmakodinamika ta’ natalizumab kien evalwat fi studju ta’ 12-il pazjent b’ms.

the first study involved 17 patients with ahus who did not respond to or could not be treated with plasma exchange or infusion.
fl-ewwel studju ħadu sehem 17-il pazjent bl-ahus li ma rrispondewx jew li ma setgħux jiġu kkurati bi skambju tal-plażma jew b’infużjoni.

if tma is diagnosed, prompt treatment is required (considering plasma exchange) and immediate discontinuation of avonex is recommended.
jekk tma tkun iddijanjostikata, kura fil-pront hija meħtieġa (jikkunsidra tibdil fil-plażma) u t-twaqqif immedjat ta 'avonex huwa rakkomandat.

supplemental dosing is recommended when soliris is administered to ahus patients receiving plasma infusion or exchange (see section 4.2).
dożaġġ supplimentari hu rakkomandat meta soliris jingħata lil pazjenti b’ahus [li jkunu qed jirċievu infużjoni jew skambju ta’ plażma (ara sezzjoni 4.2).

iris occurs in almost all tysabri pml patients after withdrawal or removal of the medicinal product, e.g. by plasma exchange (see section 5.2).
iris iseħħ kważi fil-pazjenti kollha b’pml li jieħdu l-prodott mediċinali wara l-‘irtirar jew it-tneħħija ta’ tysabri, eż permezz ta’ bdil tal-plażma (ara sezzjoni 5.2).